In the last topic, I popularized what is hepatocellular carcinoma interventional therapy with patients, and in this topic, I would like to talk about four types of hepatocellular carcinoma interventional therapy commonly used in clinical practice. I. Traditional hepatic artery chemoembolization (c-TACE) Traditional interventional therapy is the most widely used in clinical practice, and the embolic drugs used are mainly super-liquidated iodine oil and gelatin sponge particles. During the procedure, the doctor inserts the catheter from the femoral artery or radial artery to the hepatic artery, firstly performs arteriography to clearly show the liver lesion and its blood supply, then selectively inserts the tumor blood supplying artery and infuses part of the chemotherapeutic drugs such as fluorouracil and oxaliplatin, and then mixes another part of the chemotherapeutic drugs with super liquefied iodine oil to form an emulsion for embolization to achieve the effect of inducing ischemic necrosis of the tumor. DC-Bead drug-borne microsphere intervention (DEB-TACE) Drug-borne microsphere embolization chemotherapy (DEB-TACE) is used to treat primary and metastatic tumors of the liver, including primary liver cancer and various liver metastatic tumors. The DC-Bead microspheres are slowly injected and pushed through the tumor to ensure that the microspheres precisely block each of the feeding arteries. DEB-TACE requires standardized slow injection therapy, which requires more patience and care than traditional TACE and takes longer than traditional TACE, usually 1-2 hours. . Hepatic artery infusion chemotherapy (HAIC) Hepatic artery infusion chemotherapy is not a new technique of liver cancer interventional treatment, in fact, it was mainly used for patients with liver metastases from intestinal cancer at first. The most common chemotherapy that tumor patients are exposed to is intravenous chemotherapy, in which the drug is dripped from the vein in the arm. The chemotherapy drug will first enter the heart from a peripheral vein, then be pumped by the heart into the aorta, and then be shunted through the aorta into various organs and tissues throughout the body, including tumor tissue. As we can see, in order to get the chemotherapy drugs from the vein into the heart and finally distributed to various organs and finally into the tumor, a big detour is made and the concentration of chemotherapy drugs is diluted in layers during the road, which brings inevitable harm to other organs and tissues without tumor. Hepatic artery infusion chemotherapy directly avoids the detour and pumps chemotherapeutic drugs slowly into the vessels supplying tumor tissues, so that the local drug concentration of the lesion can reach up to tens or even hundreds of times of that of peripheral intravenous chemotherapy, which gives it the advantage of high local control rate and low systemic side effects. Transarterial catheterization radioembolization (TARE), also known as selective internal radiation therapy (SIRT), is a new therapy to achieve localized internal radiation in the tumor by injecting radioactive spheres (such as yttrium-90) into the liver tumor vessels. On one hand, radioembolization achieves embolization of tumor blood vessels through microsphere particles, and on the other hand, through the microspheres entering inside the tumor, radiation energy is slowly released to kill nearby cancer cells, so that tumor tissues receive higher radiation doses while normal liver tissues and other organs of the body receive only lower radiation doses, achieving therapeutic efficacy with fewer side effects. Selective internal radiation therapy is very expensive, and although it is carried out in some foreign countries and Hong Kong, it has not yet been approved by FDA, and it has not been carried out in China yet. In recent years, the technology of hepatocellular carcinoma interventional treatment is changing rapidly and every moment. The Department of Liver Oncology of Zhongshan Hospital of Fudan University has been the first to carry out interventional treatment for liver cancer in China since 1978, and has accumulated tens of thousands of cases of interventional treatment for primary liver cancer and liver metastases, carrying out interventional treatment 5000 times a year, accumulating a lot of experience in interventional treatment for liver cancer, and the efficacy and safety of which are widely recognized by the same at home and abroad, hoping to provide individualized and precise treatment for more liver cancer patients and improve their prognosis. We hope to provide more liver cancer patients with individualized and precise treatment and improve the prognosis of liver cancer patients.